Study of Higher than 80 years Old patients Keeping frailty Under the Therapy of mirabegron for Overactive bladder

Study of Higher than 80 years Old patients Keeping frailty Under the Therapy of mirabegron for Overactive bladder - HOKUTO study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045996

Enrollment

Registered

2021-11-08

Start date

2016-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the OAB symptom score (OABSS); i.e., a total score of >3 points and an urgency score of >2 points

Exclusion criteria

Exclusion criteria: urinary tract infection bladder outlet obstruction: urethral stricture neurogenic bladder severe liver dysfunction, renal dysfunction, cardiovascular disease drug allergy history of surgery contraindication of mirabegron post-void residual urine >50mL

Design outcomes

Primary

Measure	Time frame
overactive bladder symptom score (OABSS) 12 weeks after treatment	—

Secondary

Measure	Time frame
(1)frailty: VES-13 (2)cognitive function: MMSE, MOCA-J (3)international prostate symptom score (IPSS) (4)OAB-q (5)uroflowmetry post-void residual urine (6)safety: adverse event	—

Countries

Japan

Contacts

Public ContactTakahiko Mitsui

University of Yamanashi Urology

tmitsui@yamanashi.ac.jp0552739643

Outcome results